摘要
目的探讨利脑心片联合重组人尿激酶原治疗急性心肌梗死的临床疗效。方法选取2018年10月—2020年10月在延安市人民医院治疗的144例急性心肌梗死患者,根据随机数字法分为对照组(72例)和治疗组(72例)。对照组患者静脉滴注注射重组人尿激酶原,50 mg/次,先将20 mg溶于10 mL生理盐水,3 min内静推完毕,余30 mg溶于100 mL生理盐水,30 min内静脉滴注完毕,1次/d。治疗组患者在对照组的基础上饭后口服利脑心片,3片/次,3次/d。两组患者治疗7d。观察两组患者临床疗效,比较治疗前后两组患者临床症状好转时间,肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)和肌钙蛋白T(TnT)指标,及血清炎性因子白细胞介素6(IL-6)、白细胞介素8(IL-8)、C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)水平。结果治疗后,治疗组患者总有效率为98.61%,明显高于对照组的87.51%(P<0.05)。治疗后,治疗组患者临床症状好转时间均早于对照组(P<0.05)。治疗后,两组患者CK-MB、LDH、TnT及血清炎性因子IL-6、IL-8、CRP、TNF-α水平均明显低于对照组(P<0.05);治疗后,治疗组这些指标改善优于对照组(P<0.05)。结论利脑心片联合注射用重组人尿激酶原治疗急性心肌梗死效果显著,临床症状缓解较快,有效改善冠状动脉血流量,降低心肌炎性反应,药物不良反应较小。
Objective To investigate the clinical study of Linaoxin Tablets combined with recombinant human prourokinase in treatment of acute myocardial infarction. Methods Patients(144 cases) with acute myocardial infarction in Yanan People’s Hospital from October 2018 to October 2020 were randomly divided into control(72 cases) and treatment(72 cases) group. Patients in the control group were iv administered with Recombinant Human Prourokinase for injection, 50 mg/time, 20 mg dissolved into normal saline 10 mL, and completed within 3 min, then 30 mg dissolved into normal saline 100 mL, intravenous drip completed within 30 min, once daily. Patients in the treatment group were po administered with Linaoxin Tablets, 3 tablets/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, the improvement time of clinical symptoms,the indexes of CK-MB, LDH, TnT, the levels of serum inflammatory factor IL-6, IL-8, CRP, and TNF-α in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.61%, which was significantly higher than that of the control group(87.51%)(P < 0.05). After treatment, the relief time of clinical symptom in the treatment group was earlier than that in the control group(P < 0.05). After treatment, the improvement time of clinical symptoms in treatment group was earlier than that in control group(P < 0.05). After treatment, the levels of CK-MB, LDH, TnT and serum inflammatory factors IL-6, IL-8, CRP and TNF-α in two groups were significantly lower than those in control group(P < 0.05).After treatment, the improvement of these indexes in the treatment group was better than the control group(P < 0.05). Conclusion The effect of Linaoxin Tablets combined with recombinant human prourokinase in treatment of acute myocardial infarction is obvious,the clinical symptoms are relieved quickly, the coronary blood flow is improved effectively, the myocardial inflammatory reaction is reduced, and the adverse drug reaction is less.
作者
杜玲玲
杨蓉
张亚敏
李成祥
DU Ling-ling;YANG Rong;ZHANG Ya-min;LI Cheng-xiang(Intensive Care Unit,Yan’an People’s Hospital,Yanan 716000,China;Department of Internal Medicine-Cardiovascular,the First Affiliated Hospital of Air Force Military Medical University,Xi'an 710000,China)
出处
《现代药物与临床》
CAS
2021年第12期2531-2535,共5页
Drugs & Clinic
基金
国家自然科学基金资助项目(81670229)。
